Education
About Us
Working with TipRanks
Follow Us
Medicus Pharma Ltd (MDCX)
NASDAQ:MDCX
MDCX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.80 - $6.00
Previous CloseN/A
Volume5.92K
Average Volume (3M)70.05K
Market Cap
$48.91M
Enterprise Value$28.43M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.00
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding13,414,801
10 Day Avg. Volume64,640
30 Day Avg. Volume70,053
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio1101.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.00Price Target Upside260.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Medicus Pharma Ltd News
PremiumTipRanks Newswire
While Big Pharma Stalls, One Small-Cap Breaks Out
PremiumTipRanks Newswire
Healthcare Climbs as Tech Stumbles in 2025 Shift
PremiumCompany Announcements
Medicus Pharma Secures $4.2 Million for Innovative Skin Treatment Trials
PremiumCompany Announcements
Medicus Pharma Advances Non-Invasive Skin Cancer Treatment in UAE---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMedicus announced positive interim data from its ongoing P2 trial evaluating SkinJect in nodular basal cell carcinoma, showing a >60% complete response rate and positive safety profile.
Market PotentialNodular basal cell carcinoma affects approximately 3 million patients annually in the US, presenting a significant market opportunity for SkinJect.
Bears Say
Financial NeedsMedicus Pharma's cash position, along with funds from the U.S. IPO, should support operations into Q2 2025, although additional capital will be needed for future trials.
Operational RisksMedicus plans to hold a Type C meeting with the FDA to discuss the potential of expanding the trial to a registration study, which could position SkinJect as a widely adopted treatment.
---
Options Prices
Currently, No data available
---
Ownership Overview
17.44% Insiders
12.47% Other Institutional Investors
70.09% Public Companies and
Individual Investors
MDCX FAQ
What was Medicus Pharma Ltd’s price range in the past 12 months?
Medicus Pharma Ltd lowest stock price was $1.80 and its highest was $6.00 in the past 12 months.
What is Medicus Pharma Ltd’s market cap?
Medicus Pharma Ltd’s market cap is $48.91M.
When is Medicus Pharma Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medicus Pharma Ltd’s earnings last quarter?
Medicus Pharma Ltd released its earnings results on Aug 22, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.161 by -$0.339.
Is Medicus Pharma Ltd overvalued?
According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued.
Does Medicus Pharma Ltd pay dividends?
Medicus Pharma Ltd does not currently pay dividends.
What is Medicus Pharma Ltd’s EPS estimate?
Medicus Pharma Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicus Pharma Ltd have?
Medicus Pharma Ltd has 13,414,801 shares outstanding.
What happened to Medicus Pharma Ltd’s price movement after its last earnings report?
Medicus Pharma Ltd reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.161. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Medicus Pharma Ltd?
Currently, no hedge funds are holding shares in MDCX
---
Medicus Pharma Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (260.66% Upside)
$11.00 (260.66% Upside)
Insider Transactions
Bought Shares
Worth C$1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.52%
12-Months-Change
Fundamentals
Return on Equity
-525.44%
Trailing 12-Months
Asset Growth
198.29%
Trailing 12-Months
Company Description
Medicus Pharma Ltd
Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company focused on investing in novel life sciences and bio-technology companies through Food and Drug Administration (FDA) approved clinical trials. The Company identifies, acquires and advances relatively de-risked clinical stage assets through clinical development and commercialization. The Company is exploring to expand its drug development pipeline through acquisitions and partnerships. The Company, through its subsidiary, SkinJect, Inc., is focused on the development of a drug delivery system using novel dissolvable microneedle arrays for the treatment of certain skin cancers. SkinJect is a novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma.
---
MDCX Stock 12 Month Forecast
Average Price Target
$11.00
▲(260.66% Upside)
Technical Analysis
Mersana Therapeutics
―
Whitehawk Therapeutics
―
Reviva Pharmaceuticals Holdings
―
Milestone Pharmaceuticals
―
Immix Biopharma, Inc.
―
Best Analysts Covering MDCX
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+16.70%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +16.70% per trade.
---